XML 37 R12.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSET AND GOODWILL	12 Months Ended
INTANGIBLE ASSET AND GOODWILL	Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSET AND GOODWILL	INTANGIBLE ASSET AND GOODWILL Intangible Asset The Company maintained a definite-lived intangible asset related to developed product rights for Auryxia. The intangible asset was initially recorded at fair value and was stated net of accumulated amortization. The Company amortized the intangible asset using the straight-line method over the estimated useful life of six years. The intangible asset was fully amortized as of December 31, 2024. The Company recorded $36.0 million in amortization expense during each of the years ended December 31, 2024 and 2023 related to the developed product rights for Auryxia. Goodwill As of December 31, 2025 and 2024, the Company had goodwill of $59.0 million recorded in connection with the December 2018 merger with Keryx Biopharmaceuticals, Inc., or Keryx. The Company has not identified any goodwill impairment to date.